Background: Retroperitoneal leiomyosarcomas are neoplasma which are best treated with complete exeresis.

Aim: We reported three new cases of retroperitoneal Leiomyosarcoma operated during last ten years.

Cases: The authors reported 3 cases of Retroperitoneal leiomyosarcomas in 3 patients (2 men and a woman) aged respectively 53, 55 and 57 year-old. Incomplete resection was performed in the 3 cases because of the important local extension. All patients died 18, 19 et 51 months after diagnosis.

Download full-text PDF

Source

Publication Analysis

Top Keywords

retroperitoneal leiomyosarcomas
8
cases retroperitoneal
8
[retroperitoneal leiomyosarcoma
4
leiomyosarcoma report
4
report cases]
4
cases] background
4
background retroperitoneal
4
leiomyosarcomas neoplasma
4
neoplasma best
4
best treated
4

Similar Publications

Retroperitoneal leiomyosarcoma diagnosis and management in a chronic kidney disease context: A case report.

Int J Surg Case Rep

November 2024

Department of Surgery A La Rabta Hospital, Tunis, Tunisia; Faculty of medicine of Tunis, Tunis El Manar University, Tunis, Tunisia.

Introduction And Importance: While the treatment approach for sarcomas seems straightforward and well-defined, we often encounter several diagnostic or therapeutic challenges in clinical practice. This article presents a case of retroperitoneal leiomyosarcoma in a patient with chronic kidney disease, highlighting the complexity of managing such cases.

Case Report: A 63-year-old woman with a history of chronic kidney disease presented with a progressively enlarging mass in her right flank.

View Article and Find Full Text PDF

Sarcoma: Last Year's Practice Changing Papers.

Ann Surg Oncol

December 2024

Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Background: In 2023 and 2024, a wide variety of new studies have been published in the field of soft tissue sarcomas, representing the enormous heterogeneity of sarcoma histotypes, anatomical location, treatment variability, and biological behavior.

Patients And Methods: This article summarizes the, in our view, seven most important publications in the field that will have an impact on the surgical practice and future treatment strategies of our patients.

Results: In the last year, we gained more insight in the genetic background of patients with sarcoma from a large Australian study, which will have an impact on future counseling and screening of our patients.

View Article and Find Full Text PDF

Comparing epidemiological and clinical data from RPS patients documented in a German cancer registry to a cohort from TARPSWG reference centres.

J Cancer Res Clin Oncol

November 2024

Department of Surgery, Sarcoma Unit, University Medical Center Mannheim (UMM) and Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.

Purpose: Retroperitoneal sarcomas (RPS) are rare, heterogeneous tumours. Treatment recommendations are mainly derived from cohorts treated at reference centres. The applicability of data from cancer registries (CR) is controversial.

View Article and Find Full Text PDF

A 59-year-old man presented with abdominal mass and weight loss. Computed tomography revealed a 20 cm mass in the vicinity of the left kidney. A tumor biopsy was performed and diagnosed with leiomyosarcoma.

View Article and Find Full Text PDF

Primary inferior vena cava(IVC) leiomyosarcoma (LMS) is an extremely rare retroperitoneal mesenchymal tumour with < 500 cases reported in literature so far. Patients always present with nonspecific complaints, hence delaying the actual diagnosis, and they are associated with poor oncological outcomes. Differentiating primary leiomyosarcoma from other pathologies affecting IVC-like bland thrombus, retroperitoneal liposarcomas and other tumours infiltrating IVC secondarily may be difficult at times.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!